Jack A. Schalken

Rotterdam, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 144 publications

Intrapatient tumour heterogeneity and clonal evolution in an autopsy study of metastatic salivary gland cancer.

Intrapatient tumour heterogeneity and clonal evolution in an autopsy study of metastatic salivary gland cancer.

Journal: Molecular oncology

Published: February 04, 2026

Real-world effectiveness of molecular-matched therapies in salivary gland cancer.

Real-world effectiveness of molecular-matched therapies in salivary gland cancer.

Journal: ESMO open

Published: January 08, 2026

Impact of Heterogeneous DNA Methylation on the Accuracy of Quantitative Methylation-Specific PCR for Detecting DNA Hypermethylation in Prostate Cancer.

Impact of Heterogeneous DNA Methylation on the Accuracy of Quantitative Methylation-Specific PCR for Detecting DNA Hypermethylation in Prostate Cancer.

Journal: International journal of molecular sciences

Published: December 29, 2025

Anti-neoplastic effects of the antipsychotic drug penfluridol in preclinical prostate cancer models.

Anti-neoplastic effects of the antipsychotic drug penfluridol in preclinical prostate cancer models.

Journal: Frontiers in oncology

Published: August 14, 2025

Molecular reflex testing in patients with early metastatic castration-resistant prostate cancer within the PROMPT-study.

Molecular reflex testing in patients with early metastatic castration-resistant prostate cancer within the PROMPT-study.

Journal: British journal of cancer

Published: December 03, 2024

Discovery of RNA Biomarkers for Prostate Cancer Using Cross-Platform Transcriptomics.

Discovery of RNA Biomarkers for Prostate Cancer Using Cross-Platform Transcriptomics.

Journal: International journal of molecular sciences

Published: October 15, 2024

Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial.

Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: August 13, 2024

A randomized phase II trial on the addition of dutasteride to combined androgen blockade therapy versus combined androgen blockade therapy alone in patients with advanced or metastatic salivary duct carcinoma - the DUCT study protocol.

A randomized phase II trial on the addition of dutasteride to combined androgen blockade therapy versus combined androgen blockade therapy alone in patients with advanced or metastatic salivary duct carcinoma - the DUCT study protocol.

Journal: BMC cancer

Published: July 25, 2024

Hyaluronic acid: Function and location in the urothelial barrier for bladder pain syndrome/interstitial cystitis, an in vitro study.

Hyaluronic acid: Function and location in the urothelial barrier for bladder pain syndrome/interstitial cystitis, an in vitro study.

Journal: PloS one

Published: June 24, 2024

Impact of TP53 loss-of-function alterations on the response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients.

Impact of TP53 loss-of-function alterations on the response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients.

Journal: Theranostics

Published: February 01, 2024

TTLL12 has a potential oncogenic activity, suppression of ligation of nitrotyrosine to the C-terminus of detyrosinated α-tubulin, that can be overcome by molecules identified by screening a compound library.

TTLL12 has a potential oncogenic activity, suppression of ligation of nitrotyrosine to the C-terminus of detyrosinated α-tubulin, that can be overcome by molecules identified by screening a compound library.

Journal: PloS one

Published: November 24, 2023

Exploring the potential of circulating tumour DNA to monitor treatment response in salivary duct carcinoma patients of the CABO-ASAP trial.

Exploring the potential of circulating tumour DNA to monitor treatment response in salivary duct carcinoma patients of the CABO-ASAP trial.

Journal: Oral oncology

Published: October 30, 2023

Showing 1-12 of 144

Last Updated: 09/26/2026